High Evidence
Research Overview
Mazdutide Research for Type 2 Diabetes
An evidence-based overview of research examining Mazdutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
A phase 2 trial showed clinically meaningful glycemic control, with HbA1c reduced 1.41-1.67% vs placebo in Chinese patients with type 2 diabetes. The DREAMS-3 head-to-head trial vs semaglutide (N=349) is designed around a combined HbA1c <7% and ≥10% weight loss endpoint, with results pending. Under regulatory review in China for a T2D indication.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.